Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atogepant for the Prevention of Migraine in Japanese Subjects With Episodic Migraine
NCT05861427Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Jul 2023
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of atogepant in episodic migraine (4 arms), sponsored by AbbVie Inc. Primary endpoints: Change From Baseline in Mean Monthly Migraine Days at 12 weeks and Number of Participants Experiencing With Adverse Events at 12 weeks. Started Jul 2023; status: completed.
02
Drugs
atogepant
03
Conditions
episodic migraine
Beyond the preview
Go deeper on NCT05861427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05861427.